High-Sensitivity Troponin I in Addition to Guideline-Based Care in EMS

Launched by KAROLINSKA INSTITUTET · Jun 4, 2025

Keywords

ClinConnect Summary

The TIGER study is a clinical trial that aims to improve the early detection of heart attacks in patients experiencing chest pain before they arrive at the hospital. Currently, many heart attacks go undetected until patients get to the emergency room, which can delay treatment. This study will test a quick blood test called Troponin I, which can help identify heart attacks while patients are still in the ambulance. Participants will be randomly assigned to either receive the usual emergency care or the usual care plus the Troponin I test, allowing researchers to see which approach leads to faster and more accurate diagnoses.

To be eligible for the study, participants must be adults aged 18 and older who are experiencing chest pain or whose condition suggests a heart attack. However, individuals with serious trauma or those unable to give consent will not be included. Throughout the trial, participants can expect to receive standard emergency treatment, and their care will be closely monitored. The study has been approved by ethical authorities to ensure the safety and well-being of all participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chestpain / discomfort and/or
• • Clinical suspicion of myocardial infarction by the prehospital personeel
• Exclusion Criteria:
• • Patients suffering from a trauma and conveyed to the trauma level 1 hospital.
• • Missing valid social security number
• • Not beeing able to give informed consent
• • Not a primary assignment